Fig. 3: Virtual population responses to TDB and loncastuximab tesirine combination therapy by cycle and loncastuximab tesirine dosing regimen.
Dashed line: separation between nonresponders and responders. Tumor response classification based on ref. 48. Lonca loncastuximab tesirine, TDB T-cell-dependent bispecific antibody.
